Kura Oncology Added to Russell 3000® Index
June 26 2017 - 7:30AM
Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage
biopharmaceutical company focused on the development of precision
medicines for oncology, today announced that it has been added to
the broad U.S. market Russell 3000® Index as part of FTSE
Russell’s annual reconstitution of its stock indexes, effective at
the opening of U.S. markets today.
Annual reconstitution of Russell U.S. indexes captures the 4,000
largest U.S. stocks as of the end of May, ranking them by total
market capitalization. Membership in the U.S. all-cap Russell 3000®
Index, which remains in place for one year, means automatic
inclusion in the large-cap Russell 1000® Index or small-cap Russell
2000® Index as well as the appropriate growth and value style
indexes. FTSE Russell determines membership for its Russell indexes
primarily by objective, market-capitalization rankings and style
attributes.
“We are excited to have been added to the Russell 3000®
Index,” said Troy Wilson, Ph.D., J.D., President and CEO of Kura
Oncology. “The inclusion is a reflection of Kura’s growth and
should increase our visibility to investors and provide additional
liquidity for our shares.”
Russell indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for
active investment strategies. Approximately $8.4 trillion in assets
are benchmarked against Russell’s U.S. indexes. Russell indexes are
part of FTSE Russell, a leading global index provider.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company
committed to realizing the promise of precision medicines for the
treatment of cancer. The company’s pipeline consists of small
molecule drug candidates that target cancer signaling pathways
where there is a strong scientific and clinical rationale to
improve outcomes by identifying those patients most likely to
benefit from treatment. Kura Oncology’s lead drug candidate is
tipifarnib, a farnesyl transferase inhibitor, which is currently
being studied in multiple Phase 2 clinical trials. Kura’s pipeline
also includes KO-947, an ERK inhibitor, currently in a Phase 1
trial, and KO-539, an inhibitor of the menin-MLL protein-protein
interaction, currently in preclinical testing. For additional
information about Kura Oncology, please visit the company’s website
at www.kuraoncology.com.
Forward-Looking Statements
This news release contains certain forward-looking statements
that involve risks and uncertainties that could cause actual
results to be materially different from historical results or from
any future results expressed or implied by such forward-looking
statements. Such forward-looking statements include statements
regarding Kura Oncology’s future expectations, beliefs, goals,
plans or prospects. Factors that may cause actual results to differ
materially include the risk that compounds that appeared promising
in early research or clinical trials do not demonstrate safety
and/or efficacy in later preclinical studies or clinical trials,
the risk that Kura Oncology may not obtain approval to
market its product candidates, uncertainties associated with
performing clinical trials, regulatory filings and applications,
the risks associated with reliance on outside financing to meet
capital requirements, and other risks associated with the process
of discovering, developing and commercializing drugs that are safe
and effective for use as human therapeutics, and in the endeavor of
building a business around such drugs. You are urged to
consider statements that include the words "may," "will," "would,"
"could," "should," "believes," "estimates," "projects," "promise, "
"potential," "expects," "plans," "anticipates," "intends,"
"continues," "designed," "goal," or the negative of those words or
other comparable words to be uncertain and forward-looking. For a
further list and description of the risks and uncertainties the
Company faces, please refer to the Company's periodic and other
filings with the Securities and Exchange Commission, which are
available at www.sec.gov. Such forward-looking statements are
current only as of the date they are made, and Kura
Oncology assumes no obligation to update any forward-looking
statements, whether as a result of new information, future events
or otherwise.
CONTACT INFORMATION
INVESTOR CONTACT:
Robert H. Uhl
Managing Director
Westwicke Partners, LLC
(858) 356-5932
robert.uhl@westwicke.com
CORPORATE COMMUNICATIONS CONTACT:
Mark Corbae
Vice President
Canale Communications
(619) 849-5375
mark@canalecomm.com
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Apr 2023 to Apr 2024